Multivariate analysis of prognostic factors for complete remission and survivals after SMILE therapy
| Significant factor . | P . | Hazard ratio . | 95% confidence interval . |
|---|---|---|---|
| CR | |||
| Whole cohort | |||
| Interim | |||
| Sex | .011 | 3.593 | 1.333-9.687 |
| Age | .027 | 1.046 | 1.005-1.088 |
| Completion | |||
| Sex | .008 | 4.168 | 1.456-11.918 |
| Age | .011 | 1.058 | 1.013-1.105 |
| Albumin | .023 | 0.913 | 0.844-0.987 |
| Newly diagnosed | |||
| Interim | |||
| KIPI | .007 | 2.654 | 1.304-5.401 |
| Completion | |||
| Albumin | .017 | 0.884 | 0.800-0.978 |
| Age | .023 | 1.074 | 1.010-1.143 |
| Relapsed/refractory | |||
| Interim | |||
| Sex | .029 | 6.667 | 1.210-36.741 |
| Completion | |||
| Sex | .015 | 7.000 | 1.454-33.696 |
| Survivals | |||
| OS | |||
| Whole cohort | |||
| IPI | .001 | 1.758 | 1.253-2.466 |
| Age | .023 | 1.029 | 1.004-1.055 |
| Newly diagnosed | |||
| Bone marrow involvement | .001 | 5.186 | 1.950-13.795 |
| Age | .001 | 1.073 | 1.029-1.118 |
| DFS | |||
| Whole cohort | |||
| IPI | .033 | 1.840 | 1.049-3.227 |
| Newly diagnosed | |||
| Site | .005 | 8.490 | 1.938-37.188 |
| Age | .011 | 1.162 | 1.035-1.303 |
| Bone marrow involvement | .031 | 6.924 | 1.188-40.348 |
| Relapsed/refractory | |||
| Performance status | .003 | 6.086 | 1.864-19.872 |
| Significant factor . | P . | Hazard ratio . | 95% confidence interval . |
|---|---|---|---|
| CR | |||
| Whole cohort | |||
| Interim | |||
| Sex | .011 | 3.593 | 1.333-9.687 |
| Age | .027 | 1.046 | 1.005-1.088 |
| Completion | |||
| Sex | .008 | 4.168 | 1.456-11.918 |
| Age | .011 | 1.058 | 1.013-1.105 |
| Albumin | .023 | 0.913 | 0.844-0.987 |
| Newly diagnosed | |||
| Interim | |||
| KIPI | .007 | 2.654 | 1.304-5.401 |
| Completion | |||
| Albumin | .017 | 0.884 | 0.800-0.978 |
| Age | .023 | 1.074 | 1.010-1.143 |
| Relapsed/refractory | |||
| Interim | |||
| Sex | .029 | 6.667 | 1.210-36.741 |
| Completion | |||
| Sex | .015 | 7.000 | 1.454-33.696 |
| Survivals | |||
| OS | |||
| Whole cohort | |||
| IPI | .001 | 1.758 | 1.253-2.466 |
| Age | .023 | 1.029 | 1.004-1.055 |
| Newly diagnosed | |||
| Bone marrow involvement | .001 | 5.186 | 1.950-13.795 |
| Age | .001 | 1.073 | 1.029-1.118 |
| DFS | |||
| Whole cohort | |||
| IPI | .033 | 1.840 | 1.049-3.227 |
| Newly diagnosed | |||
| Site | .005 | 8.490 | 1.938-37.188 |
| Age | .011 | 1.162 | 1.035-1.303 |
| Bone marrow involvement | .031 | 6.924 | 1.188-40.348 |
| Relapsed/refractory | |||
| Performance status | .003 | 6.086 | 1.864-19.872 |
KIPI indicates Korean prognostic score.